Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer progressing on enzalutamide: cohorts 4 and 5 of the phase 2 KEYNOTE-199 study.

Autor: Graff JN; Oregon Health and Science University, Portland, OR, USA. graffj@ohsu.edu., Hoimes CJ; Case Comprehensive Cancer Center, University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, OH, USA.; Duke University School of Medicine, Durham, NC, USA., Gerritsen WR; Radboud University Medical Center, Nijmegen, Netherlands., Vaishampayan UN; University of Michigan and Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA., Elliott T; NHS Lothian, Edinburgh, UK., Hwang C; Henry Ford Health System, Detroit, MI, USA., Ten Tije AJ; Amphia Hospital, Breda, Netherlands., Omlin A; Onkozentrum Zurich, University of Zurich and Tumorzentrum Hirslanden Zurich, Zurich, Switzerland., McDermott RS; Tallaght University Hospital, Dublin, Ireland., Fradet Y; CHU de Québec-Université Laval, Québec City, QC, Canada., Tagawa ST; Weill Cornell Medical College, New York, NY, USA., Kilari D; Medical College of Wisconsin, Milwaukee, WI, USA., Ferrario C; Jewish General Hospital, Montreal, QC, Canada., Uemura H; Yokohama City University Medical Center, Yokohama, Japan., Jones RJ; University of Glasgow, Glasgow, UK., Fukasawa S; Chiba Cancer Center, Chiba, Japan., Peer A; Rambam Health Care Campus, Haifa, Israel., Niu C; MSD China, Beijing, China., Poehlein CH; Merck & Co., Inc., Rahway, NJ, USA., Qiu P; Merck & Co., Inc., Rahway, NJ, USA., Suttner L; Merck & Co., Inc., Rahway, NJ, USA., de Wit R; Erasmus University Medical Center, Rotterdam, Netherlands., Schloss C; Merck & Co., Inc., Rahway, NJ, USA., de Bono JS; The Royal Marsden Hospital NHS Foundation Trust and the Institute of Cancer Research, London, UK., Antonarakis ES; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.; University of Minnesota, Masonic Cancer Center, Minneapolis, MN, USA.

Publikováno v: Prostate cancer and prostatic diseases [Prostate Cancer Prostatic Dis] 2024 Aug 12. Date of Electronic Publication: 2024 Aug 12.

Pilot study of the implementation of G8 screening tool, Cognitive screening assessment and Chemotherapy Toxicity assessment in older adults with cancer in a Tertiary University Hospital in Ireland.

Autor: AlSendi M; Department of Medical Oncology, St. Vincent's University Hospital, Elm Park, Dublin 4, Ireland. mahaalsindi@gmail.com., Flynn CR; Department of Medical Oncology, St. Vincent's University Hospital, Elm Park, Dublin 4, Ireland., Khan MR; Department of Medical Oncology, St. Vincent's University Hospital, Elm Park, Dublin 4, Ireland., Selvadurai P; Department of Medical Oncology, St. Vincent's University Hospital, Elm Park, Dublin 4, Ireland., Crown J; Department of Medical Oncology, St. Vincent's University Hospital, Elm Park, Dublin 4, Ireland., McDermott RS; Department of Medical Oncology, St. Vincent's University Hospital, Elm Park, Dublin 4, Ireland., Walshe JM; Department of Medical Oncology, St. Vincent's University Hospital, Elm Park, Dublin 4, Ireland., Fennelly DW; Department of Medical Oncology, St. Vincent's University Hospital, Elm Park, Dublin 4, Ireland., Hanrahan EO; Department of Medical Oncology, St. Vincent's University Hospital, Elm Park, Dublin 4, Ireland., Doherty M; Department of Medical Oncology, St. Vincent's University Hospital, Elm Park, Dublin 4, Ireland., Higgins MJ; Department of Medical Oncology, St. Vincent's University Hospital, Elm Park, Dublin 4, Ireland.

Publikováno v: Irish journal of medical science [Ir J Med Sci] 2024 Feb; Vol. 193 (1), pp. 45-50. Date of Electronic Publication: 2023 Jul 14.

Corrigendum to "Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study" [Eur. Urol. (2023)].

Autor: Plimack ER; Fox Chase Cancer Center, Philadelphia, PA, USA. Electronic address: Elizabeth.Plimack@fccc.edu., Powles T; Barts Health NHS Trust and the Royal Free NHS Foundation Trust, Barts Cancer Institute, London, UK; Queen Mary University of London, London, UK., Stus V; Dnipro State Medical University, Dnipro, Dnipropetrovsk Oblast, Ukraine., Gafanov R; Russian Scientific Center of Roentgenology and Radiology, Moscow, Russia., Nosov D; Central Clinical Hospital With Outpatient Clinic, Moscow, Russia., Waddell T; The Christie NHS Foundation Trust, Manchester, UK., Alekseev B; P. A. Herzen Moscow Oncology Research Institute, Ministry of Health of the Russian Federation, Moscow, Russia., Pouliot F; CHU of Québec and Laval University, Québec, QC, Canada., Melichar B; Palacký University Medical School and Teaching Hospital, Olomouc, Czech Republic., Soulières D; Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada., Borchiellini D; Centre Antoine Lacassagne, Université Côte d'Azur, Nice, France., McDermott RS; Adelaide and Meath Hospital, University College Dublin, Belfield, Dublin, Ireland., Vynnychenko I; Sumy Regional Oncology Center, Sumy State University, Sumy, Sumy Oblast, Ukraine., Chang YH; Taipei Veterans General Hospital, Taipei, Taiwan., Tamada S; Bell Land General Hospital, Osaka, Japan., Atkins MB; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA., Li C; Merck & Co., Inc., Rahway, NJ, USA., Perini R; Merck & Co., Inc., Rahway, NJ, USA., Rhoda Molife L; MSD UK, London, UK., Bedke J; University Hospital, Eberhard Karls University Tübingen, Tübingen, Germany., Rini BI; Vanderbilt-Ingram Cancer Center, Nashville, TN, USA.

Publikováno v: European urology [Eur Urol] 2023 Nov; Vol. 84 (5), pp. e123-e124. Date of Electronic Publication: 2023 Sep 02.